Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enveric Biosciences, Inc.AMRH · Entity 8193 | Chief Financial Officer | September 12, 2018 | September 14, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enveric Biosciences, Inc.
Report date September 12, 2018 · Filed September 14, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 | Direct | 200,000 |
Reported balance
After 2018-09-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-09-12 · Grant · Acquired 200,000 · Balance 200,000 F1: The options vest on the first anniversary of the grant date. The options will expire on the sixth anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest on the first anniversary of the grant date. The options will expire on the sixth anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2018 Filed Sep 14, 2018 20:19 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | GrantOption (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0000921895-18-002601 · form410211002pat_09142018.xml · derivative · entry 1 Patel Viraj J · CIK 0001389623 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · derivative.exercise_date: The options vest on the first anniversary of the grant date. The options will expire on the sixth anniversary of the grant date. F1 · derivative.expiration_date: The options vest on the first anniversary of the grant date. The options will expire on the sixth anniversary of the grant date. Read SEC document |
| May 04, 2017 Filed May 8, 2017 21:11 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | GrantOption (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $6.59 | $0.00 |
DisclosureSEC source: 0000921895-17-001341 · form410211002_05082017.xml · derivative · entry 1 Patel Viraj J · CIK 0001389623 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2022-05-04 F1 · derivative.exercise_date: The Option vests as follows: (a) as to 25,000 shares of common stock of the Issuer ("Stock), on May 4, 2018, (b) as to a further 25,000 shares of Stock, on May 4, 2019, and (c) as to the remaining 25,000 shares of Stock, on May 4, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.